Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

R. D'Ambrosio, L. Pasulo, M. Puoti, M. Vinci, M. Schiavini, S. Lazzaroni, A. Soria, F. Gatti, B. Menzaghi, A. Aghemo, F. Capelli, M.G. Rumi, L. Morini, A. Giorgini, M.G. Pigozzi, A. Rossini, F. Maggiolo, A. Pan, M. Memoli, O. SpinelliP. Del Poggio, V. Saladino, A. Spinetti, A. De Bona, A. Capretti, C. Uberti-Foppa, P. Bonfanti, N. Terreni, F. Menozzi, A.E. Colombo, O. Giglio, R. Centenaro, M. Borghi, C. Baiguera, V. Picciotto, S. Landonio, A. Gori, C. Magnani, F. Noventa, S. Paolucci, P. Lampertico, S. Fagiuoli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)379-387
Number of pages9
JournalJournal of Hepatology
Volume70
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • DAA
  • Effectiveness
  • Glecaprevir
  • HCV
  • Pibrentasvir
  • RAS
  • Real-life
  • Safety
  • SVR
  • bilirubin
  • glecaprevir plus pibrentasvir
  • interferon
  • virus RNA
  • adult
  • aged
  • Article
  • chronic hepatitis C
  • chronic kidney failure
  • clinical effectiveness
  • cohort analysis
  • depression
  • drug safety
  • drug tolerability
  • drug withdrawal
  • estimated glomerular filtration rate
  • fatigue
  • female
  • headache
  • Hepatitis C virus genotype 1
  • Hepatitis C virus genotype 2
  • Hepatitis C virus genotype 3
  • human
  • Human immunodeficiency virus infection
  • hypertensive crisis
  • insomnia
  • intention to treat analysis
  • jaundice
  • liver stiffness
  • longitudinal study
  • major clinical study
  • male
  • mixed infection
  • multicenter study (topic)
  • nausea
  • nonhuman
  • patient compliance
  • platelet count
  • priority journal
  • pruritus
  • relapse
  • retrospective study
  • side effect
  • sustained virologic response
  • treatment duration
  • treatment response
  • vomiting

Cite this

D'Ambrosio, R., Pasulo, L., Puoti, M., Vinci, M., Schiavini, M., Lazzaroni, S., Soria, A., Gatti, F., Menzaghi, B., Aghemo, A., Capelli, F., Rumi, M. G., Morini, L., Giorgini, A., Pigozzi, M. G., Rossini, A., Maggiolo, F., Pan, A., Memoli, M., ... Fagiuoli, S. (2019). Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 70(3), 379-387. https://doi.org/10.1016/j.jhep.2018.11.011